We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$1.32B
1-Year Est. Return
76.62%
This Fund
S&P 500
This Quarter
Est. Return
+21.46%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$270M
AUM Growth
+$101M
(+59%)
Cap. Flow
+$72.1M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
57.23%
Holding
37
New
8
Increased
17
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$6.55M |
| 2 |
Illumina
ILMN
|
+$5.6M |
| 3 |
Gilead Sciences
GILD
|
+$4.99M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$4.42M |
| 5 |
KITE
Kite Pharma, Inc.
KITE
|
+$3.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$3.76M |
| 2 |
Pacific Biosciences
PACB
|
+$1.61M |
| 3 |
ADVM
Adverum Biotechnologies
ADVM
|
+$1.13M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$828K |
| 5 |
Curis
CRIS
|
+$301K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.69% |
| 2 | Materials | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
CytomX Therapeutics
CTMX
$690M
| $2.75M | 1.02% |
177,500
| – | – |
|
27
CALL
Myriad Genetics
MYGN
$285M
| $2.58M | 0.96% |
+100,000
| New | +$2.12M |
|
28
Ovid Therapeutics
OVID
$435M
| $2.33M | 0.86% |
+221,700
| New | +$2.89M |
|
|
JNCE
29
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.25M | 0.83% |
160,000
+30,000
| +23% | +$642K |
|
30
Editas Medicine
EDIT
$407M
| $2.24M | 0.83% |
133,333
| – | – |
|
|
MDRX
31
CALL
DELISTED
Veradigm Inc. Common Stock
MDRX
| $1.91M | 0.71% |
+150,000
| New | +$1.82M |
|
32
Fate Therapeutics
FATE
$291M
| $1.78M | 0.66% |
+550,000
| New | +$2.11M |
|
|
AMRS
33
DELISTED
Amyris Inc.
AMRS
| $1.59M | 0.59% |
500,000
+100,000
| +25% | +$540K |
|
|
34
Pacific Biosciences
PACB
$441M
| $1.07M | 0.4% |
300,000
-400,000
| -57% | -$1.61M |
|
|
35
Curis
CRIS
$10M
| $161K | 0.06% |
43
-72
| -63% | -$301K |
|
|
ADVM
36
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-42,000
| Closed | -$1.13M |
|
|
MDRX
37
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-310,000
| Closed | -$3.76M |
|
Similar funds
MDSL
CP
HCM
MRL
SWM
B
WGAM
CRAM
Casdin Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Casdin Capital held 37 positions worth $270M, up 59% from $170M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Casdin Capital deployed $72.1M of net new capital in Q2 2017, opening 8 new positions and adding to 17 existing holdings. Its largest new stake was Illumina: 32,382 shares worth $5.47M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Materials.
On the sell side, the largest reduction was Pacific Biosciences, an estimated $1.61M trimmed.
- Casdin Capital's largest Q2 2017 buy was Illumina: 32,382 shares worth $5.47M.
- Casdin Capital added most to Clovis Oncology, Inc. in Q2 2017, an estimated $6.55M increase.
- Casdin Capital's biggest Q2 2017 reduction was Pacific Biosciences, cutting an estimated $1.61M.
- Casdin Capital fully exited Veradigm Inc. Common Stock in Q2 2017, selling an estimated $3.76M.
- Casdin Capital's ten largest holdings make up 57% of its $270M portfolio in Q2 2017.
- Casdin Capital opened 8 new positions and closed 2 in Q2 2017.
- Casdin Capital's portfolio value rose 59% quarter-over-quarter to $270M.
Based on Casdin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.